ImmunityBio valuation
$6.04Change from previous close: +0.25%Absolute change: +$0.02
Valuation
The average price target of 4 analysts is $14.25.
Data as of November 15, 2026
ImmunityBio compared with similar companies
| Metric | ImmunityBio | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| Price/sales | 35.1 | 8.80 | 6.44 – 14.5 | High |
| Gross margin | 98.8% | 91.1% | 59.7% – 95.3% | High |
| Operating margin | -150.2% | 11.5% | -27.0% – 24.5% | Low |
| Net margin | 0.0% | 0.0% | -12.9% – 15.4% | Middle |
| ROE | 122.9% | 8.3% | -9.7% – 38.5% | High |
| Debt/equity | -1.17 | 0.12 | 0.02 – 0.67 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $6.4B
- Enterprise value
- $7.37B
- P/E (trailing 12 months)
- -8.70
- Forward P/E
- -54.7
- Price/book
- -8.53
- EV/EBITDA
- -28.6
- EV/revenue
- 40.4
Profitability and growth
- ROA
- -30.4%
- ROIC
- -69.1%
- Revenue growth (year over year)
- 52.3%
- Earnings growth (year over year)
- 110.5%
Financial health
- Total cash
- $334.33M
- Total debt
- $1.3B
- Current ratio
- 4.27
- Quick ratio
- 3.96
- Altman Z-Score
- -9.35
- Piotroski F-Score
- 2.00
Dividends
- Dividend yield
- 0.0%
Analysts and estimates
- Average price target
- $14.25
- Median price target
- $14.50
- High price target
- $16.00
- Low price target
- $12.00
- Analysts with a price target
- 4
- Consensus
- Strong buy
- Forward EPS
- -$0.11
- EPS estimate, current year
- -$0.93
Shares and trading
- Beta
- 0.17
- Average volume
- 12.64M
- Shares outstanding
- 1.06B
- Float
- 410.68M
- Institutional ownership
- 20.5%
- Insider ownership
- 62.1%
- Short interest (% of float)
- 31.1%
- Short ratio (days)
- 8.32
